Zilucoplan in patients with acute hypoxic respiratory failure due to COVID-19 (ZILU-COV): A structured summary of a study protocol for a randomised controlled trial

Zilucoplan in patients with acute hypoxic respiratory failure due to COVID-19 (ZILU-COV): A structured summary of a study protocol for a randomised controlled trial

Abstract Objectives Zilucoplan (complement C5 inhibitor) has profound effects on inhibiting acute lung injury post COVID-19, and can promote lung repair mechanisms that lead to improvement in lung oxygenation parameters. The purpose of this study is to investigate the efficacy and safety of Zilucopl...

Full description

Bibliographic Details
Main Authors: Jozefien Declercq, Cedric Bosteels, Karel Van Damme, Elisabeth De Leeuw, Bastiaan Maes, Ans Vandecauter, Stefanie Vermeersch, Anja Delporte, Bénédicte Demeyere, Marnik Vuylsteke, Marianna Lalla, Trevor Smart, Laurent Detalle, René Bouw, Johannes Streffer, Thibo Degeeter, Marie Vergotte, Tanguy Guisez, Eva Van Braeckel, Catherine Van Der Straeten, Bart N. Lambrecht
Format: Article
Language:English
Published: BMC 2020-11-01
Series:Trials
Subjects:
COVID-19
Randomised controlled trial
protocol
zilucoplan
complement system
complement C5 inhibition
Online Access:http://link.springer.com/article/10.1186/s13063-020-04884-0

Internet

http://link.springer.com/article/10.1186/s13063-020-04884-0

Similar Items